FSSAI Orders Removal of ‘ORS’ from Food and Beverage Labels

New Delhi– The Food Safety and Standards Authority of India (FSSAI) has directed all food and beverage manufacturers to immediately remove the term “ORS” (Oral Rehydration Solution) from product labels, citing misleading claims about health benefits.

The order aims to prevent consumer confusion, as only medically certified ORS products can use the term. Non-compliance will attract fines up to ₹10 lakh. Manufacturers have 30 days to update packaging. FSSAI emphasized stricter enforcement to protect public health.

Background: Public Interest Litigation

The regulatory intervention follows a nearly decade-long campaign by Hyderabad-based paediatrician Dr. Sivaranjani Santosh against sugar-rich beverages falsely marketed as ORS. In 2022, she filed a Public Interest Litigation (PIL) in the Telangana High Court challenging beverages that claimed to be ORS but failed to meet WHO-recommended electrolyte and glucose standards.

Her petition highlighted the potential health risks, especially to children and diabetic patients, and her complaints reached the Ministry of Health and Family Welfare, prompting regulatory scrutiny.

Court and Regulatory Actions

The Telangana High Court directed FSSAI and the Drug Controller General of India to respond, recognising the public health implications of misleading ORS claims.

In April 2022, FSSAI issued its first restriction, but in July the regulator temporarily allowed companies holding valid trademarks to continue production until the Controller General of Patents, Designs and Trademarks issued a final decision.

Health Risks from Mislabelled Beverages

WHO-approved ORS has a total osmolarity of 245 mOsm/L, with precise quantities of sodium, potassium, chloride, and dextrose. In contrast, many marketed products contained up to 120 grams of sugar per litre, with minimal electrolytes, posing serious health risks.

Related Posts

Cancer cure must not be hostage to Big Pharma

In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients